REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD

Biopharma executive with more than 35 years of leadership across C-suite and board roles

Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors.

Mark Altmeyer brings more than 35 years of experience as a biopharma executive and board leader across large pharma and high-growth biotech companies focusing on multiple therapeutic areas. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings. Altmeyer is recognized for fostering high-performing teams, aligning investors and management around clear value-creation priorities.

“Mark is distinguished by a rare blend of board-level leadership and operational excellence covering the full biopharma lifecycle, combining entrepreneurial drive with disciplined governance and a strategic, stakeholder-oriented mindset,” said Jean Marie Duvall, Chief Executive Officer and Co-Founder of ReproNovo. “He has successfully guided companies through critical development and strategic inflection points, capabilities that will be highly valuable as we globally advance RPN-001 and RPN-002 across four indications in fertility and women’s health.”

Most recently, Altmeyer served as Founder and CEO of Arvelle Therapeutics, where he led the company’s transatlantic build-out, secured $200 million in financing and successfully completed a $1 billion acquisition by Angelini Pharma within two years. His earlier roles include CCO at Axovant, as well as senior commercial and general management positions at Bristol Myers Squibb and Otsuka. At Otsuka, he led the launch and expansion of Abilify to become the top selling pharmaceutical product in the U.S. in 2013, increasing revenue to over $7 billion. Across Altmeyer’s career, his leadership has spanned multiple therapeutic areas and business models, from primary care and specialty pharma to rare disease and hospital-driven markets.

In addition to his executive experience, Altmeyer adds extensive board-level leadership across the biotech lifecycle, from early-stage development through late-stage growth and exit. He currently serves as Chairman of AM-Pharma and Calluna Pharma and holds non-executive or independent director roles at several public and private life sciences companies. From 2016 to 2018, Altmeyer served as an Independent Director at Myovant Sciences, which was subsequently acquired by Sumitomo Pharma in a transaction valued at approximately $3 billion.

Commenting on his appointment, Mark Altmeyer said: “ReproNovo is addressing critical therapeutic gaps in areas that have seen limited innovation, despite these being really large markets. I look forward to working with the Board and management team to maximize these highly differentiated products, create value and ultimately bring these products to patients.”

ABOUT REPRONOVO:
ReproNovo is a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. ReproNovo’s lead clinical compound, RPN-001 (leflutrozole), is currently being evaluated in a U.S. Phase 2 trial in men with low sperm count and low testosterone (NCT06993155). RPN-002 (nolasiban) is in development to improve embryo implantation success rates and for the management of adenomyosis. ReproNovo is financed by Jeito Capital, BNP Paribas Asset Management Alts (formerly AXA IM Alts), founding investor M Ventures, Ysios Capital and ALSA Ventures. Headquartered in Lausanne, Switzerland, the company has its primary development team in Copenhagen, Denmark and an additional development site in Barcelona, Spain, with clinical and operational team members also based in the U.S. For more information, visit the Company’s website at www.repronovo.com or follow us on LinkedIn.

CONTACT INFORMATION:
ReproNovo
Rue de Langallerie 11
1003 Lausanne, Switzerland
info@repronovo.com

MEDIA CONTACT:
MC Services AG
Brittney Sojeva
repronovo@mc-services.eu
+49 211 529 252 14

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

• Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading to substantially higher systemic peak drug level and, ultimately, to sufficient exposure with lower doses
• Superior PK profile enables significantly reduced oral dosing amount, supporting this next-generation compound as a promising new oral development candidate for Alzheimer’s disease

Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, presented preclinical data showcasing the improved pharmacokinetic (PK) profile of a next-generation amyloid-beta (Aβ) aggregation modulator for Alzheimer’s disease. The poster, entitled, “New oral prodrug of the Aβ aggregation modulator GAL-201 shows significantly improved pharmacokinetic profile”, was presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2026: advances in science and therapy), being held in Copenhagen, Denmark, March 17-21, 2026. 

“The data presented at AD/PD™ 2026 demonstrate the rapid absorption and significantly higher peak plasma concentrations of this new prodrug compared to the parent compound,” said Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix. “These characteristics make this prodrug a promising new oral Aβ-targeting development candidate that could offer enhanced efficacy and patient-friendly dosing for the long-term treatment of Alzheimer’s disease.”

Prodrug demonstrates rapid and complete absorption, enabling reduced oral doses, important for long-term administration
Galimedix has several compounds in development that neutralize soluble, toxic forms of Aβ early in the aggregation process, and thereby prevent neurodegeneration. Preclinical studies show consistent disease-modifying effects across Alzheimer’s, glaucoma and dry AMD models mediated by peak plasma concentrations. While the oral bioavailability in rats was shown to be acceptable, improved bioavailability would reduce oral drug doses, which would be an advantage for patients. Thus, Galimedix derived next generation molecules with the goal of improving PK properties based on absorption and systemic exposure considerations.

This superior PK profile enables significantly reduced oral doses, which is particularly important given the need for long-term administration for patients with Alzheimer’s disease.

The poster can be accessed here: AD/PD 2026: Galimedix Poster

About Galimedix Therapeutics, Inc. 
Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in Alzheimer’s disease, dry age-related macular degeneration (AMD) and glaucoma – Galimedix’s initial areas of focus.  For more information, visit www.galimedix.com and follow us on LinkedIn.

Contact 
Alexander Gebauer, MD, PhD 
Galimedix Therapeutics, Inc. 
Co-founder and Executive Chairman  
info@galimedix.com  

Media inquiries: 

Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

Presentations explore the role of glutamatergic modulation in treatment-resistant schizophrenia (TRS) across preclinical and clinical research

Milan, Italy, and Morristown, NJ, USA, March 20, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy.

Workshop
Wednesday, March 25, 2026
3:30-5:30 PM CET – Room: Auditorium

• Modulation of Glutamate in Patients With TRS: Results From Trials With Evenamide
  (within the workshop “Use of Biomarkers in Evaluating Novel Treatments for Patients with Schizophrenia”)

Posters
Thursday, March 26, 2026
12:00-2:00 PM CET – Room: Cavaniglia

• T10: Novel Findings from a Neurodevelopmental Animal Model of Schizophrenia Support Long-Term Clinical Benefits of Evenamide in Treatment-Resistant Schizophrenia

Friday, March 27, 2026
12:00-2:00 PM CET – Room: Cavaniglia

• F7: Novel Add-On Glutamate Modulation with Evenamide in Treatment-Resistant Schizophrenia: Updates from the Phase III, Potentially Pivotal, ENIGMA-TRS Program

Saturday, March 28, 2026
12:00-2:00 PM CET – Room: Cavaniglia

• S10: Unique Benefits of Evenamide on Social Functioning and Life Engagement in Patients with Treatment-Resistant Schizophrenia or Inadequate Response to Second-Generation Antipsychotics
   

About ENIGMA-TRS
The ENIGMA-TRS pivotal Phase III program consists of ENIGMA-TRS 1 and ENIGMA-TRS 2. ENIGMA-TRS 1, initiated in August 2025, is an international, one-year, double-blind, placebo-controlled study in at least 600 patients to evaluate the efficacy, tolerability, and safety of evenamide 15 mg and 30 mg twice daily as an add-on therapy to current antipsychotics, including clozapine, compared to placebo. ENIGMA-TRS 2, initiated in December 2025, is a Phase III, international, 12-week, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of evenamide 15 mg twice daily as an add-on therapy to current antipsychotics, including clozapine, compared to placebo, in patients suffering from TRS. ENIGMA-TRS 2 will enroll at least 400 patients.

About evenamide
Evenamide is a novel, orally available new chemical entity with a unique mechanism of action distinct from all currently marketed antipsychotics. It acts by selectively blocking voltage-gated sodium channels (VGSCs) and exhibits no biological activity at more than 130 other central nervous system (CNS) targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of subtherapeutic doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide meaningful benefits for patients who do not adequately respond to current APs, including those on clozapine. Importantly, the benefits seemed to persist for a substantial time after evenamide had been degraded, explaining the long-term effects seen in clinical studies. Through its novel glutamatergic modulation, evenamide represents a first-in-class approach aimed at addressing the unmet needs of patients with schizophrenia who are resistant to existing treatments.

About treatment-resistant schizophrenia (TRS)
A significant proportion of patients with schizophrenia show virtually little to no beneficial response to currently available antipsychotic (AP) treatments, leading to a diagnosis of treatment-resistant schizophrenia (TRS). TRS is defined as no or inadequate symptom relief despite treatment with therapeutic doses of two APs from two different chemical classes for an adequate period. It is estimated that approximately 15% of patients develop TRS from the onset of illness, and about one-third to 50% of patients with schizophrenia overall. Emerging scientific evidence supports abnormalities in glutamate neurotransmission in TRS, not targeted by current APs, along with normal dopaminergic synthesis, to explain the lack of clinical benefit of most typical and atypical antipsychotics, which act primarily on dopamine receptors. These insights underline the need for novel therapeutic approaches that target the underlying glutamatergic dysfunction in schizophrenia, offering hope for patients who currently have limited or no effective treatment options.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: www.newron.com

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
Paul Sagan, LaVoieHealthScience; +1 617 865 0041, psagan@lavoiehealthscience.com

Ad hoc announcement

Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million

Korneuburg, Austria, March 19, 2026

The Executive Board of Marinomed Biotech AG (“Company”) resolved today, with the approval of the Supervisory Board, to carry out a capital increase against cash contributions—while preserving the subscription rights of existing shareholders—by partially utilizing the authorized capital provided for in Section 5(6) of the Articles of Association, in order to meet short-term capital requirements, and to increase the share capital from the current EUR 1,839,940 by up to EUR 459,985 through the issuance of up to 459,985 new no-par value bearer shares (“New Shares”) with a notional proportionate amount of the share capital of EUR 1.00 per share to up to EUR 2,299,925 (the “Capital Increase”). Existing shareholders of the Company (“Existing Shareholders”) will be granted subscription rights (“Subscription Rights”) on a 4:1 basis, i.e., for every four existing shares, one New Share may be subscribed for at a subscription price of EUR 14.00 per New Share (“Subscription Price”). The goal of the transaction is to generate gross proceeds of at least EUR 2 million.

Because the Company has not yet received sufficient payments from the transfer of the Carragelose business to Unither Pharmaceuticals (“Unither”), the Company has a short-term capital requirement to cover its anticipated liquidity needs of approximately EUR 2 million until mid of the fiscal year 2026. The net proceeds from the capital increase are therefore to be used to fulfill the restructuring plan and close the financing gap.

The Company will make use of the prospectus exemptions provided for in Article 1(4)(db) and Article 1(5)(ba) of Regulation (EU) 2017/1129 (“Prospectus Regulation”), as amended, in connection with the offering of the New Shares and the admission of the New Shares to trading on the Vienna Stock Exchange. The document required for this purpose pursuant to Annex IX of the Prospectus Regulation will be filed in electronic form with the Financial Market Authority (FMA), as the competent authority of the home Member State, prior to the commencement of the public offering and will be made available to the public at the same time as it is filed with the FMA via the website www.marinomed.com.

The record date for the entitlement of existing shareholders to subscribe for New Shares is March 25, 2026, at 11:59 p.m. CEST (“Record Date”). The subscription period is scheduled to begin on March 26, 2026 9:00 a.m. Central European Time and is expected to end on April 9, 2026 5:40 p.m. Central European Time, although the subscription period may be extended at any time. The subscription rights will not be tradable on the Vienna Stock Exchange. Any New Shares not subscribed for through the exercise of subscription rights in connection with the subscription offer (“Rump Shares”) will be offered following the subscription offer as part of a prospectus-exempt private placement (“Rump Placement”) to eligible institutional investors and selected non-institutional investors within the European Economic Area at the Subscription Price. A binding commitment has been received from an institutional investor who, as of today, does not yet hold any shares in the Company, to subscribe for and acquire New Shares in the total amount of EUR 1 million at the Subscription Price as part of the Rump Placement.

This announcement is made in accordance with Article 17 of the Market Abuse Regulation (EU) No. 596/2014.

Disclaimer:

The New Shares and Subscription Rights have not been and will not be registered under any foreign securities laws—in particular under the U.S. Securities Act of 1933, as amended (“Securities Act”) – with foreign securities authorities and may not be offered or sold, in particular in the United States of America (“U.S.”), without registration or an exemption from the registration requirements under the Securities Act. This announcement is not intended for distribution in the U.S. or within the U.S. and may not be distributed or forwarded to publications with general circulation in the U.S. Foreign shareholders may be subject to restrictions on the exercise of their subscription rights. Foreign shareholders are therefore urged to inform themselves of the restrictions applicable to them regarding the exercise of subscription rights. This announcement is neither an offer to sell nor a solicitation of an offer to subscribe for or purchase securities in countries where such an offer or solicitation is legally prohibited.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Disclaimer 

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. 

Press conference
MEDICLIN invites you to the 2026 virtual press conference on the financial statements for the year 2025
               
Offenburg, 19 March 2026 – MEDICLIN Aktiengesellschaft (Ticker: MED; WKN 659 510) invites you to its 2026 virtual press conference on the financial statements fort the year 2025. The event will take place on
Friday, 27 March 2026 at 11.00 am (CET).

The Management Board of MEDICLIN will report on the 2025 financial year, current developments at MEDICLIN and the outlook for 2026 in a webcast.

Following the presentation by the Management Board, you will have the opportunity to ask questions. The presentation will be held in German.

To participate in the press conference, please register at the following link (German only):

MEDICLIN virtual press conference on the financial statements for the year 2023

You will then receive the link to the webcast and the dial-in details for the telephone conference. Please note that whilst the webcast provides an audio feed via your internet browser, you will need to dial in by telephone to actively participate and ask questions.

Please dial in 10 minutes before the start of the event.

The replay of the webcast (without the Q&A session) will be available on the MEDICLIN website soon after the press conference.

We look forward to your participation.

CONTACT
Head of Investor Relations and Sustainability
Ender Gülcan | T. +49 781488326 | ender.guelcan@mediclin.de
MEDICLIN AG | Okenstraße 27 | 77625 Offenburg

MEDICLIN Aktiengesellschaft is one of Germany’s leading healthcare providers, with a clear focus on medical rehabilitation. MEDICLIN operates 31 clinics, six long-term care facilities, and ten medical care centers across Germany. MEDICLIN employs approximately 9,900 people. Through a strong network, MEDICLIN offers integrated care ranging from the initial doctor’s visit through surgery and subsequent rehabilitation to outpatient follow-up care. Medical and therapeutic staff, as well as nursing staff, work together in close coordination. MEDICLIN tailors the care and support provided to people in need of care to their individual needs and personal requirements. MEDICLIN is a company of the ASKLEPIOS Group.www.mediclin.de
 

Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard

• Advisory Board to provide strategic guidance as well as financial and industry expertise to support Secarna’s management team and shareholders in shaping and executing on its long-term growth trajectory

Martinsried (Munich), Germany, March 19, 2026 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the establishment of an Advisory Board to support the Company’s growth trajectory. Financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard have been appointed members of the Board.

The Advisory Board aims to provide strategic guidance as well as financial and industry expertise to support sustainable business growth as Secarna strives to fulfill on its mission to transform untreatable medical conditions into treatable ones by leveraging its AI-empowered OligoCreator^® platform to identify and characterize oligonucleotide therapeutics and bringing its lead compound SECN-15 to clinical proof of concept (POC).

“We are delighted to welcome such experienced industry leaders to our Advisory Board at this pivotal stage of Secarna’s development,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “We look forward to building on their industry perspectives and combined experience to help drive our long-term growth objectives.”

Jens Holstein, former CFO of BioNTech SE, commented: “I’m excited to join Secarna’s Advisory Board and support the Company as it continues its journey as a leading developer of oligonucleotide therapeutics. I look forward to contributing my financial and corporate strategy expertise in the life sciences, biotech and pharma environment to help guide sustainable growth and long-term value creation.”

Richard Mark Engelhard, representing shareholder Engelhard Arzneimittel GmbH & Co KG, stated: “Secarna’s recent development demonstrates the strength of its AI-empowered platform as well as it’s growing proprietary pipeline with SECN-15 as novel, potential best-in-class oligonucleotide in the field of oncology. I am pleased to join the Advisory Board and further support the management team as the Company continues to scale and execute on a compelling long-term growth and value-creation trajectory. Having supported Secarna for many years as a shareholder, I’m excited to now contribute in this expanded role.”

Richard Mark Engelhard is General Manager of Engelhard Arzneimittel GmbH & Co. KG, one of the leading brand-name manufacturers in the OTC medicines segment.

Jens Holstein has over 30 years of leadership experience in the life sciences and biopharmaceutical sector. In 2021 he joined BioNTech SE as CFO and retired from this position mid of 2025. BioNTech is well-known for its pioneering work in immunotherapies and for its mRNA vaccines, including its COVID-19 vaccine Comirnaty^®. At BioNTech, he led the financial strategy that supported the company’s growth into a global, fully integrated immunotherapy leader. Prior to this position, he served for almost 10 years as CFO of MorphoSys AG. He was instrumental in transforming the company into a fully integrated biopharmaceutical player. MorphoSys has been listed in Germany (MDAX) and the US (NASDAQ). He also held executive roles within the Fresenius SE Group, including Regional CFO for EMEA and Regional CFO of Fresenius Kabi Asia Pacific Ltd. He also served as Managing Director at Fresenius ProServe GmbH and CFO of its subsidiary Wittgensteiner Kliniken AG. He is currently a non-executive member of the Board of Directors of the US-listed diagnostic company Veracyte Inc. and serves as Chairman of the audit committee. He holds a degree in Business Administration (Dipl. Kfm) from the University of Münster.

About Secarna Pharmaceuticals

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities. With the Company’s proprietary AI-empowered OligoCreator® platform, which includes multiple delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By delivering these novel therapeutics to the cells, organs, or tissues where they are needed, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Secarna’s unique OligoCreator^® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine. www.secarna.com

Contact

Secarna Pharmaceuticals GmbH & Co. KG
Konstantin Petropoulos, PhD, MBA
CEO
Phone: +49 (0)89 215 46 375
info@secarna.com

For media inquiries

MC Services AG
Anne Hennecke/Vera Lang
Phone: +49 (0)211 52 92 52 16

Email: secarna@mc-services.eu

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026.
During a conference call on Thursday, March 26, 2026, at 10:00 a.m., CEO Dr. Dirk Pleimes and CBO Henner Kollenberg will present the financial results for the 2025 fiscal year, a review of key operational developments and milestones, and an outlook on Pentixapharm’s clinical and strategic priorities.
 

• Conference call on March 26, 2026, at 10:00 a.m. CET

To participate in the conference call, please register via the following link:
Registration for Pentixapharm Holding AG – FY 2025 Review & Management Outlook

About Pentixapharm Holding AG
Pentixapharm is a biopharmaceutical company with advanced clinical trials in the field of radiotherapeutics. Headquartered in Berlin, the company develops precision medicine diagnostics and therapeutics in the fields of oncology and cardiology with the aim of sustainably improving patient care.
 
For further information about Pentixapharm Holding AG please visit www.pentixapharm.com.
 
 

Hamburg, Germany, March 19, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.

Initiation of the first‑in‑human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue’ candidate jointly generated through Evotec’s powerful and fully integrated drug discovery platform. This platform combines high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities, selectively prompting cancer cells to eliminate disease‑driving proteins. As a result of this clinical progression, Evotec will receive a milestone payment of $10 million.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec said:

“In this unique collaboration, we follow a systematic approach to discovering molecular glues with tremendous therapeutic potential. Together with Bristol Myers Squibb, and building on Evotec’s PanOmics and PanHunter platforms, we have identified a broad portfolio of high-potential molecular glue drug candidates that are now beginning to enter clinical development. The initiation of this Phase 1 clinical trial marks the first clinical milestone in the strategic protein degradation partnership with BMS. Molecular glues have the potential to address significant unmet medical need not only in oncology, but far beyond, by targeting previously undruggable, disease-causing proteins and thereby aiming to reshape future standards of care.“

BMS-986506 was developed under the strategic protein degradation partnership between Evotec and Bristol Myers Squibb. The collaboration combines PanOmics, Evotec’s high-performance multi-omics screening platform as well as PanHunter, Evotec’s AI-supported data omics analytics platform with BMS’s industry-leading library of CELMoDs™ agents. Initiated in 2018 and expanded in 2022, the collaboration is continuing to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.

About Molecular Glue Degraders

Conventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins “undruggable”. Conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.

Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and degradation of the recruited protein. This event-driven mechanism of action significantly expands the range of the druggable proteome. The molecular glue is not degraded in the process and can trigger the degradation process many times over, thus leading to longer-lasting therapeutic effects.

About Evotec’s Strategic Collaboration with Bristol Myers Squibb in Molecular Glues

In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. BMS is a leader in this field based on its unique library of CELMoDs™ agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.

Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec’s leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec’s PanOmics data analysis platform PanHunter. It supports the integration and analysis of these data sets and thereby enables the selection of the most promising CELMoDs™ for further progression into lead optimization.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Viromed Medical AG: Anna Heinen appointed to the Supervisory Board

Rellingen, March 19, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has appointed a new member to its Supervisory Board. Anna Heinen was appointed to the Supervisory Board by court order. She succeeds Frank Otto, who resigned from the Supervisory Board for personal reasons.

Dr. Thomas Gutschlag, Chairman of the Supervisory Board of Viromed Medical AG, states: “I am very pleased that we have gained a qualified Supervisory Board member in Anna Heinen with proven expertise in the areas of corporate strategy, transformation, and governance. With her experience, she will provide important impetus for the further development of our company. At the same time, on behalf of the entire Supervisory Board and the Management Board, I would like to express our sincere thanks to Frank Otto for his commitment over the past three years. He provided valuable support to Viromed during the company’s crucial growth phase.”

Anna Heinen has been a member of the Supervisory Board of Smartaxxess Operation AG, a fintech company focused on planning, valuation and financing for small and medium-sized enterprises, since 2022. She is also a qualified Supervisory Board member according to Deutsche Börse standards, as well as being a member of ARMID – Aufsichtsräte Mittelstand in Deutschland e.V. Professionally, Ms. Heinen has been responsible for the corporate strategy of e-fellows.net GmbH & Co. KG, an HR service provider owned by McKinsey & Company and Zeitverlag, for many years. Since 2023, she has also supported medium-sized companies regularly in succession and transformation processes as an independent management consultant.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de

Press contact

E-Mail: viromed@kirchhoff.de

Media release

PolyPeptide strengthens financing structure through expansion of existing credit facility

Baar, 19 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the strengthening of its financing structure through the expansion of its existing credit facility. 

PolyPeptide has expanded its existing credit facility to EUR 200 million, reinforcing its financing position. UBS continues to act as coordinator and agent of the lending syndicate, which now includes ING Bank in addition to Danske Bank and Zürcher Kantonalbank.

The expanded facility further enhances PolyPeptide’s financial flexibility as the Group advances toward its strategic objective of doubling 2023 revenue by 2028, supported by expected improvements in profitability and cash flow as well as continued customer funding for major capacity‑expansion projects. 

Juan Jose Gonzalez, CEO of PolyPeptide: “The expansion of our credit facility and the addition of ING Bank to our lending syndicate reinforce the confidence our banking partners have in PolyPeptide’s strategy and long‑term growth potential. With this increased financing capacity, we are well positioned to advance toward our ambition of doubling 2023 revenue by 2028 and to continue our growth journey from a position of solid financial strength.”

Contact

PolyPeptide Group AG
Corporate Communications
Lauren Starr
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Investor Relations
Tim Brandl
investorrelations@polypeptide.com
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.  

@PolyPeptide — follow us on LinkedIn.

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.